Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 3;15(1):118.
doi: 10.1038/s41408-025-01324-7.

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

Minoru Kanaya  1 , Masahiro Onozawa  2 , Toshihiro Matsukawa  3 , Naoki Miyashita  3 , Fumiaki Fujii  3 , Shota Yoshida  3 , Jun Nagai  3 , Masayuki Aiba  3 , Daisuke Hidaka  4 , Junichi Hashiguchi  5 , Hajime Senjo  6 , Tetsuyuki Igarashi  7 , Masahiro Chiba  8 , Satoshi Yamamoto  9 , Taku Shimizu  10 , Takashi Ishio  11 , Shota Yokoyama  12 , Ko Ebata  13 , Satoshi Iyama  14 , Tatsuo Oyake  15 , Takeshi Kondo  16 , Takanori Teshima  3
Affiliations

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

Minoru Kanaya et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: MK's spouse is an employee of AbbVie GK. TK has received honoraria from Astellas Pharma, AbbVie, Amgen, Kyowa Kirin, Nippon Shinyaku, Ono Pharmaceutical, Otsuka Pharmaceutical, Novartis, Pfizer, and Bristol-Myers Squibb; and consultancy fees from Otsuka Pharmaceutical. TT has received honoraria from Abbvie, Astellas, AstraZeneca, Novartis, Bristol-Myers Squibb, Gilead, Nippon Shinyaku, Kyowa Kirin, Janssen, and research funding from LUCA Science, Priothera SAS, Pharma Essentia Japan, Abbvie, IQVIA, CSL Behring, Cmic, Gilead, Novartis, Janssen, Chugai, Kyowa Kirin, International Advanced Medical Organization, and subsidy or donation from Chugai, Kyowa Kirin, Sumitomo Pharma.

Figures

Fig. 1
Fig. 1. Overall survival of “VEN 14” vs. “VEN 21” vs. “VEN 28”.
Overall survival stratified by venetoclax duration, 14 days administration of venetoclax (VEN 14), 21 days administration of venetoclax (VEN 21), and 28 days of venetoclax (VEN 28).
See this image and copyright information in PMC

References

    1. Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, et al. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Leuk Lymphoma. 2022;63:928–38. - PubMed
    1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. - PubMed
    1. Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024;1:100017. - PMC - PubMed
    1. Kanaya M, Mukai Y, Kobayashi M, Kajikawa S, Suzuki T, Yokoyama E, et al. Combination of low white blood cell count and impaired renal function is a risk factor for higher concentrations of venetoclax and prolonged neutropenia in AML patients with venetoclax combined regimen: real-world experience in the Japanese cohort. Blood. 2024;144:2930.
    1. Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol. 2024;99:E63–E66. - PubMed

LinkOut - more resources